2021.11.22
On November 15th 2021, Bright Peak Therapeutics (“Bright Peak”) and Livzon MabPharm, Inc. (“Livzon MabPharm”), the holding subsidiary of Livzon Pharmaceutical Group Inc. (A-share code: 000513, Hong Kong share code: 01513) (“Livzon Group”), announced that they had signed a research cooperation and technology license agreement. Livzon MabPharm licensed its recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection to Bright Peak in the form of paid non-exclusive rights for the development of new PD-1 targeted immune cytokines (PD-1 ICs), and licensed Bright Peak to use LZM009 for the development and commercialization of PD-1 ICs drugs worldwide (except in Greater China).
Livzon MabPharm is a holding subsidiary of Livzon Group, specializing in the R & D of innovative antibody drugs, fusion / recombinant protein drugs and other new biological agents used in immuno-oncology and reproductive and autoimmune diseases.
Bright peak is a private biotechnology company with headquarters in San Diego and Basel, Switzerland. It is committed to creating the next generation of cytokine immunotherapy for patients with cancer and autoimmune diseases.
JunHe was entrusted by Livzon Group to review, modify and negotiate the transaction documents. As a comprehensive law firm with long-term experience in patent and business law across China and the United States, JunHe provides its clients with high-quality, rigorous and efficient professional legal services throughout the transaction process.
This project was led by partners Mr. Li, Qi (Adam) and Mr. ZHAO, Hao (Gerry).
